Acupuncture Combined with Traditional Chinese Medicine for Allergic Rhinitis: A Protocol for Systematic Review and Meta-Analysis

Le Yan¹, Haocheng Gou¹, Jun Feng² and Lintong Dai³*

¹School of Medical and Life Sciences/Reproductive & Women-Children Hospital, Chengdu University of Traditional Chinese Medicine, China
²The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, China
³Affiliated Hospital of Panzhihua University, Panzhihua, China

Abstract

Background: Allergic Rhinitis (AR) is a prevalent yet underappreciated inflammatory disorder of nasal mucosa, which is characterized by pruritus, sneezing, rhinorrhea and nasal congestion, some studies have pointed out that if combine Traditional Chinese Medicine (TCM) with acupuncture, which can enhance the effect of acupuncture and moxibustion. However, safety and efficacy of acupuncture combined with traditional Chinese medicine for treating allergic rhinitis remain largely uncertain. In our study, we will perform the first systematic review and meta-analysis to explore the effectiveness and safety of acupuncture combined with TCM for AR.

Methods: We will search the Randomized Controlled (RCT) literatures involving acupuncture combined with TCM for treating AR in seven electric databases, including PubMed, Web of science, EMBASE, the Cochrane library, Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Wan Fang Database. We will define the total effective rate or cure rate, and recurrence rate as the primary outcomes, the Rhinoconjunctivitis Quality of Life Questionnaire (ROQLQ) score, symptom score (nasal congestion, snot, sneezing) will be regarded as the secondary outcomes. Quality assessment of included studies will be independently performed according to the Cochrane Risk of Bias tool. Meanwhile, the level of evidence for results will be assessed by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method. All analysis will be conducted by using the RevMan software V5.4.

Conclusion: The conclusion of this study will confirm safety and efficacy of acupuncture combined with TCM in the treatment of allergic rhinitis, which can provide new evidence to guide appropriate interventions on AR with acupuncture combine with TCM in future.

Systematic Review Registration: PROSPERO CRD42021247621.

Keywords: Acupuncture; AR; Meta-analysis; TCM

Abbreviations

AR = Allergic Rhinitis
TCM = Traditional Chinese medicine
CI = Confidence Interval
OR = Odds Ratio
RCTs = Randomized Controlled Trials

Background

Allergic rhinitis, abbreviated AR, is a prevalent yet underappreciated inflammatory disorder of nasal mucosa, which is characterized by pruritus, sneezing, rhinorrhea, and nasal congestion [1]. The impact of AR on quality of life is very significant. Allergic rhinitis is a major contributor to the total cost of health-related absenteeism (eg, missing work) and presenteeism (eg, showing up to work but having reduced productivity). For example, costs of AR and allergic conjunctivitis in the United States have been estimated at more than $6 billion per year [2-4]. At present, modern medicine with desensitization therapy, the use of anti-allergic drugs, antihistamines, hormones, and other improved symptoms or immune regulation, but clinical near and long-term efficacy is general, after stopping the symptoms are easy to repeat, long-term drug toxicity side effects are obvious [5]. Traditional Chinese medicine, external treatment is mostly acupuncture and moxibustion, but its remission of patients' symptoms does not last long, some studies have pointed out that if the combination of the two can greatly reduce patients' nasal congestion, runny nose and other symptoms, so that patients' life can be greatly improved [6-13]. However, there is still a lack of systematic evaluation on the efficacy and safety of acupuncture combined with traditional Chinese medicine for AR in clinical practice. Therefore, the efficacy and safety of acupuncture combine with traditional Chinese medicine for AR will be systematically evaluated and meta-analysis in this paper.
Methods

Study design

The protocol of this review will be conducted and reported in accordance with the preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) statement guidelines [14] and the corresponding checklist can be found in Additional file1. This protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247621)

Inclusion Criteria for Study Selection

Type of studies

We will estimate the publications according to the criteria of the review objectives and Participants, Interventions, Comparisons, Outcomes (PICO). Only Randomized Controlled Trials (RCTs) involving acupuncture combine with Traditional Chinese medicine, placebo treatment. Language of literature will be limited to Chinese and English. Studies that mentioned the term of “randomization” will also be considered, while studies using incorrect randomization methods will be excluded. Additionally, other designs such as in vivo, case report and non-RCTs will also be excluded.

Type of participants

Studies that enrolled patients with AR, regardless of gender, age, race, or nationality, who received acupuncture therapy with Traditional Chinese medicine will be included. However, the patients with other serious illnesses, such as cancer, cardiovascular disease, and liver and kidney disease, will be excluded.

Type of interventions

We will consider studies evaluating the following treatments including body acupuncture, scalp acupuncture, warm needle acupuncture, combine with Traditional Chinese medicine.

Type of comparators or control

We will include and classify the comparators in study as follows: (1) TCM, (2) acupuncture, (3) no treatment. Articles comparing different acupoints or different forms of acupuncture will be excluded.

All inclusion and exclusion criteria for considering studies for this review are summarized in supplementary.

Primary outcomes

Clinical efficacy, including total effective rate or cure rate, and recurrence rate will be accepted as the primary outcomes.

Secondary outcomes

The Rhinitis Quality of Life Questionnaire (RQLQ) score, symptom score (nasal congestion, snot, sneezing) will be used as secondary outcomes.

Search strategies

An electronic search will be carried out in the following databases, including PubMed, Web of science, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Wan Fang Database. Terms of Medical Subjects (MeSH) and keywords will be used individually or in combination during the query. The specific search strategy for PubMed will be taken as an example, which will be shown in Table 1. Nevertheless, the searching strategy for other databases will be minorly modified. In addition, Chinese characters with the same meaning will be used for literature retrieval in the Chinese databases.

Moreover, we will filter relevant medical journals and magazines to clarify literature which is not included in the electronic databases. Meanwhile, clinical trials registries, like the WHO International Clinical Trial Registry Platform, Chinese Clinical Registry, and ClinicalTrials.gov, will be searched for ongoing trials with unpublished data. The reference lists of all potential publications, including relevant systematic reviews, will be manually retrieved and reviewed to further locate additional trials. Incomplete data will be obtained via contacting the corresponding author.

Study collection

Two reviewers (YL and GHC) will evaluate the title and abstract of all studies for possible candidates, respectively. Any duplicate studies will be removed. After title and abstract screening, the full-text copies of all eligible studies will be downloaded for re-evaluation. Once the reviewer is uncertain about the eligibility of any study, its full text will be obtained to re-examine. An additional reviewer (DLT) will be consulted in case of disagreement. Excluded studies and the reasons of exclusion will be recorded. The specific process of study screening will be displayed in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The flow diagram of all study selection procedure is shown in figure 1.

Data extraction

Two investigators (YL and GHC) will independently perform data extraction. The general information, participants, methods, interventions, outcomes, results, adverse events, conflict of interest, ethical approval, and other information will be extracted. Furthermore, we will contact the authors for further information when the reported data is not sufficient. Besides, any disagreement will be resolved by discussion between the two authors (YL and GHC) and further disagreements will be arbitrated by the third author (FJ).

Dealing with missing data

The corresponding authors or relevant authors will be contacted by telephone or e-mail for insufficient or missing data. In case of no reply from the authors or missing data cannot be supplied, the missing data with replacement values will be imputed, treating these as if they were observed. The last observation carried forward imputation
method will be used to assume a missing value, and, then, an intention-to-treat analysis will be performed. Moreover, if possible, the sensitive analyses will be performed to assess how sensitive the results are to reasonable changes in the assumptions that are made. The potential impact of missing data on the final outcome of the review will be addressed in the discussion.

Risk of bias assessment

Two authors (YL and GHC) will assess the risk of bias with the Cochrane Collaboration’s tool for risk of bias assessment in all included studies [15]. The following domains for risk of bias will be evaluated: sequence generation, allocation sequence concealment, blinding of participants and personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias. The judgment on these items will be classified into three levels: “low risk of bias,” “high risk of bias,” or “unclear risk of bias.” The conflicts or any discrepancies will be resolved by discussion or will be judged by another reviewer (FJ) to achieve the consensus.

Quality of evidence assessment

According to grading of Recommendations Assessment, Development and Evaluation (GRADE) method [16], the evidence quality evaluation of key outcomes can be regarded as four levels: high quality, moderate quality, low quality, and very low quality [17]. Evidence quality is generally judged on the bias, inconsistency, indirectness, inaccuracy, and publication bias.

Measures of treatment effect

We will use the Review Manager software 5.4 (V5.4) [18] to carry out statistical analysis. Mean Difference (MD) or Standardized Mean Difference (SMD) will be used for continuous data. In addition, Risk Ratio (RR) or Risk Difference (RD) will be used for analysis of dichotomous data. Furthermore, the corresponding 95% Confidence Interval (CI) for each parameter will be calculated between the treatment group and the control group.

Assessment of heterogeneity

The heterogeneity will be assessed by I2 statistical test. If the I2 test is less than 50%, the fixed-effect model will be used for data synthesis. Otherwise, the random-effects model will be conducted with heterogeneous data, which I2 test between 50 and 75%. If the I2 test is higher than 75%, we will find possible reasons from both clinical and methodological perspectives and provide an explanation or conduct subgroup analysis.

Assessment of reporting bias

A funnel plot will be generated to assess reporting bias when more than 10 trials included [19].

Data synthesis

Clinical data will be imported into the RevMan software (V5.4) to perform data synthesis, and the significance threshold will be P < 0.05 on two sides. A forest plot for each parameter will be constructed to indicate the weight ratio of each incorporated study.

Sensitivity analysis

Sensitivity analysis will be conducted to monitor the robustness of primary decision made in the review process. Several decision nodes, such as sample size, methodological weakness, and missing data, will be considered. The results of the sensitivity analysis will be presented in summary tables. The risk of bias in the review process as indicated by the results of the sensitivity analysis will be discussed.

Subgroup analysis

If data is available, a subgroup analysis will be conducted according to variations in the characteristics of the trial participants and acupuncture combined with TCM treatment. When considerable heterogeneity is detected in previous analysis, a subgroup analysis will be performed if necessary.

Ethics and dissemination

Ethics approval will not be necessary, because the included publications in our study do not involve patients’ individual privacy. The main data will be extracted from published literature. This systematic review will be published in peer-reviewed journal or conference report to provide a reference for safety and efficacy of acupuncture combined with traditional Chinese medicine in the treatment of allergic rhinitis.

Discussion

According to TCM the body’s immunity is the function of what is termed the defensive Qi. Allergy in the viewpoint of TCM is a “wind” disease that penetrates from externally together with “cold” or “heat”, and impedes the defensive Qi flow in the lung, the skin and the mucous membranes [20]. Treatment of AR including acupuncture and western medicine, but a lot of the side effects of western medicine may affect the therapeutic effects. Therefore, it is necessary to find alternative therapy with higher effective. The effects of acupuncture with respect to the reduction of allergic symptoms and an improvement of the quality of life have been examined in several studies. Here
Acupuncture was reported to be effective particularly in the reduction of nasal and conjunctival signs and symptoms with improvement in the quality of life [21,22].

Acupuncture combined with TCM is a reliable method to relieve the suffering of the patient. Unfortunately, there is no comprehensive systematic review to provide enough evidence for acupuncture combined with TCM treatment for AR. Hence, carrying out a systematic review and meta-analysis from available literature to evaluate the effectiveness and safety of the acupuncture combined with TCM treatment AR is warranted. The protocol will include and integrate the latest and most comprehensive literature in this field, hoping to provide an objective treatment method for patients with AR and inspire more peer experts to implement more relevant clinical trials in the future.

However, there are some limitations in this study. Firstly, there are not enough publications on the treatment AR by using acupuncture combined with TCM. Secondly, we will only acquire the studies that were reported in Chinese or English; databases in other language such as Japanese or Korean will not be involved, which may lead to language bias.

In summary, based on rigorous study design and accurate evaluation of the literature, we expect that the review will provide evidence of acupuncture combined with TCM treatment on AR.

Acknowledgement

The authors would like to thank the editors and reviewers for their kindness and enlightening comments on this manuscript.

Author’s Contribution

YL, GHL and DLT originally conceptualized the study. All the authors contributed to the development of the protocol. YL drafted the original manuscript. GHC brought expertise in prediction model building. YL brought expertise in clinical managements of osteoarthritis. YL and GHC did the preliminary searches, piloted the study selection process, and developed the data analysis strategy, with assistance from YL, GHC, JH, and DLT. FJ polished the English language of the manuscript. DLT and FJ supervised the protocol developing process. YL acquired the funding and is the guarantor of this manuscript. All authors critically reviewed and approved the final version of the manuscript.

Funding

This research was supported by Sichuan Provincial Department of Education Fund Key Project (18ZA0203), Nanchong science and technology and intellectual property office of the project(16Y-FZ0021)

Availability of data and materials: Not applicable.

Declarations

Ethics approval and consent to participate: Not applicable

Consent for publication: Not applicable

Competing interests: The authors declare that they have no competing interests.

References


